Next-Generation Zika Virus Vaccine and Diagnostic Platform

A novel recombinant measles virus-based platform for inducing immune responses against Zika virus, comprising advanced vaccine compositions, nanoparticle-based adjuvants, and microRNA-based therapies, as well as diagnostic tools for detecting Zika virus-specific antibodies.

The original patent disclosed a recombinant measles virus expressing Zika virus prM and E proteins, but it has limitations in terms of immunogenicity, safety, and diagnostic capabilities. The new inventive concept addresses these limitations by introducing enhanced vaccine compositions, novel adjuvants, and diagnostic tools, providing a more comprehensive solution for preventing and treating Zika virus infections.

The new inventive concept comprises a system for inducing an immune response against Zika virus, featuring a recombinant measles virus expressing a Zika virus E protein variant with enhanced neutralizing antibody induction, and a nanoparticle-based adjuvant for boosting immunogenicity. Additionally, the platform includes a method for preventing Zika virus transmission, comprising administering a vaccine comprising a recombinant measles virus expressing a Zika virus prM-E protein complex, and a microRNA-based therapy for silencing Zika virus replication in infected cells. The platform also encompasses a Zika virus vaccine composition, comprising a recombinant measles virus expressing a Zika virus E protein with a modified glycosylation pattern, and a saponin-based adjuvant for enhancing immune responses. Furthermore, the platform includes a system for Zika virus diagnosis, comprising a recombinant measles virus expressing a Zika virus NS1 protein, and a lateral flow assay for detecting Zika virus-specific antibodies in a biological sample. Finally, the platform features a method for treating Zika virus infections, comprising administering a therapeutic composition comprising a recombinant measles virus expressing a Zika virus E protein, and a small molecule inhibitor of Zika virus replication.

The new inventive concept introduces several novel features, including the use of nanoparticle-based adjuvants, microRNA-based therapies, and modified glycosylation patterns, which are not present in the original patent. These features provide enhanced immunogenicity, safety, and diagnostic capabilities, making the new inventive concept non-obvious and novel compared to the original patent.

Alternative embodiments of the inventive concept could include the use of different viral vectors, such as adenovirus or lentivirus, or the incorporation of additional antigens or adjuvants to enhance immunogenicity. Variations of the diagnostic tools could include the use of different detection methods, such as PCR or ELISA, or the development of point-of-care diagnostic devices.

The new inventive concept has significant commercial potential in the vaccine and diagnostic markets, with potential applications in preventing and treating Zika virus infections, as well as diagnosing and monitoring Zika virus outbreaks. The target industries include pharmaceutical and biotechnology companies, research institutions, and government agencies focused on public health.